Deep Brain Stimulation for Essential Tremorneuro.memorialhermann.org/uploadedFiles/_Library... ·...
Transcript of Deep Brain Stimulation for Essential Tremorneuro.memorialhermann.org/uploadedFiles/_Library... ·...
Deep Brain Stimulation for Essential Tremor
Mya Schiess, MD Professor of Neurology Albert Fenoy, MD Assistant Professor of Neurosurgery
Essential Tremor (ET)
• Tremor is the most common movement disorder
• ET-roughly 5% prevalence in the general population
• Advancing age is a risk factor
• >60 years – prevalence is 9%
• Highest incidence - 6th – 8th decades
UTMOVE
Essential Tremor • Positive family history Benign Familial Tremor
• Male >Female
• Involuntary, rhythmic, oscillatory movement
• Alcohol reduces tremor in 50-90% of cases
– Most often a kinetic tremor (specific action)
– Upper extremities (arms and hands)
– Head – “yes-yes” or “no-no”
– Voice, tongue and chin
– Lower extremities (legs)
UTMOVE
Characteristic Features
• Postural and kinetic tremor with a variable amplitude and a frequency.
• Present during voluntary movement
• Over time may increase in severity and distribution
• Co-occurrence of cerebellar features like ataxia
UTMOVE
Treatment Options >>>>>>> Lifestyle changes
• Avoid or minimize exacerbating factors (e.g. stress, tremor provoking drugs).
• Consider limiting Caffeine-containing beverages
• Alcohol reduces the amplitude of ET in 2/3 of patients
UTMOVE
Pharmacologic Approaches
• 30 to 70 % improvement in tremor control at best
• Drug side effects potential to exceed benefit or worsen with increasing need to escalate dose
• 1st line Beta-blockers such as propranolol (Inderal®)
• 1st line Primidone (Mysoline®)
• Combination primidone/propranolol therapy
• 2nd Line Topirimate; Gabapentin
• Calcium channel blockers
• Carbonic anhydrase inhibitors
• Botulinum toxin type A (BOTOX®)
UTMOVE
When Should DBS therapy be considered ?
Best candidates:
• Moderate to severe tremor: Distal hand tremor and higher frequency .
• Tremor is refractory to medical management
• Limited benefit due to medication side effects.
• Tremor impairs activities of daily living or impacts quality of life
.
UTMOVE
DBS Approved Indications
• DBS Therapy is approved for the treatment of symptoms due to: – Essential Tremor
• FDA approved in 1997
– Parkinson’s disease
• FDA approved in 2002
– Dystonia
• FDA approved (HDE*) in 2003
*Humanitarian Device: Authorized by Federal Law for the use as an aid in the management of
chronic, intractable (drug refractory) primary dystonia, including generalized and segmental
dystonia, hemidystonia, and cervical dystonia, for individuals 7 years of age and older.
UTMOVE
Targets for Tremor Control
• VIM- thalamus : widely used, beneficial in upper extremity tremor.
• Bilateral VIM associated with higher prevalence of dysarthria, dysphagia and balance problems (used to achieve better results in head and voice tremor)
• Dentato-rubral tract (DRT) - available option for axial and cerebellar outflow tremor that are poorly responsive to VIM.
UTMOVE
DBS efficacy for ET
• 70-90% of Essential Tremor patients experience total or significant suppression of disabling tremor *
• Stimulation-induced adverse effects include transient paresthesia, dysarthria, and disequilibrium – Many of the side effects are temporary or
improved with adjustment of electrical parameters
* Data on File. Medtronic, Inc.
UTMOVE
Mya Schiess, MD Professor of Neurology Albert Fenoy, MD Assistant Professor of Neurosurgery
DEEP BRAIN STIMULATION FOR PARKINSONS DISEASE
Parkinson’s Disease The Basics
• What is Parkinson’s disease? 2nd most common neurodegenerative disorder after Alzheimer’s Dementia
• SLOWLY progressive • Chronic disorder • Affects an individual over 40 years of their lifespan • Very treatable, not yet curable • Non-motor symptoms precede the motor symptoms by years
to decades • No known biomarker for disease diagnosis or progression
Clinical symptoms develop after 70-80% of striatal dopamine is depleted
Corresponds to 30-50% cell death of dopaminergic neurons
UTMOVE
• Affecting 0.7% of people ≥ 65 years of age worldwide
• Incidence increases with age
• Men are slightly more affected
• Men : women 3:2
• Average age at diagnosis: 55-60 yrs
• Majority of cases (90%) are sporadic
De Lau & Breteler, Lancet Neurology 2006
UTMOVE
Parkinson’s Disease (PD): Cardinal Features and Clinical Manifestations
Motor Signs
• Bradykinesia
• Tremor at rest
• Rigidity
• Postural instability
Clinical Manifestations
• Decreased arm swing
• Hypomimia
• Hypophonia
• Micrographia
Jankovic J. Handbook of Parkinson’s Disease, 4th ed. 2007:49-76. Jankovic J. J Neurol Neurosurg Psychiatry. 2008;79:368-376.
Morgan J et al. Handbook of Parkinson’s Disease 4th ed, 2007:29-47.
UTMOVE
Nonmotor Symptoms Play an Important Role in Clinical Manifestations of PD
• Anxiety
• Constipation*
• Depression*
• Dementia
• Drooling
• Excessive daytime sleepiness
• Fatigue *
• Hyperhidrosis
• Olfactory dysfunction*
• Orthostatic hypotension
• Pain
• Psychosis
• REM sleep behavior disorder (RBD)*
• Sexual dysfunction
• Urinary urgency
*Although nonmotor symptoms occur throughout the course of PD, certain nonmotor
symptoms are considered “premotor” because onset may precede the emergence of motor
symptoms by years
UTMOVE
Parkinson’s Disease Treatment: Continuum of Interventions for Motor Symptoms
Modified from Giroux, ML et al. Cleveland Clinic Foundation 2005
Signs of levodopa “wearing-off”
Dyskinesia, “On-Off”
Motor Fluctuations
Postural Instability, Freezing, Falls, Dementia
DBS
Mild Moderate Severe
Levo-dopa, MAO inhibitors, COMT inhibitors, DA agonists
Treatment
Patient Symptoms
Disease Severity
MAO inhibitors
DA Agonists
DBS plus Levo-dopa, or DA agonist, ACH esterase inhibitor Duopa dopamine Pump
UTMOVE
TREATMENT GOALS
• The main goal is to improve quality of life- symptomatic.
• Ideally, treatments would be “neuroprotective” or “neuroregenerative”
• Currently available treatments – medical, surgical, and non-pharmacological – are very effective
UTMOVE
Physical Activity and Nutrition
• Aerobic activity-at least 30 min (Biking, Running, Tai chi, Dancing, Strength training,
Stretching, Yoga, Swimming, Boxing) • Associated with better cognitive and motor scores and with longevity
• Vitamin B12 and D3 deficiency
• Uric acid levels in men-major role in neuroprotection.
• Eating a fiber-rich diet with plenty of fluids; BEST Diet – Mediterranean Diet
• Physical & Occupational Therapy and Speech/Voice Therapy
UTMOVE
Medications • Dopamine:
Carbidopa/levodopa (Sinemet, Sinemet CR, parcopa)
Levodopa/carbidopa/entacopone (Stalevo)
Rytary
Duodopa
• Dopamine agonists – pramipexole (Mirapex), ropinirole
(Requip), bromocriptine (Parlodel), apomorphine (Apokyn),
rotigotine patch (Neupro)
• MAO-B inhibitors – selegiline (Eldepryl, Zelapar), rasagiline
(Azilect)
• COMT inhibitors – entacapone (Comtan), tolcapone (Tasmar)
• Amantadine (Symmetrel)
• Anticholinergics – trihexyphenidyl (Artane), benztropine
(Cogentin)
UTMOVE
UTMOVE
When Should DBS Therapy be Considered?
• When, despite optimized pharmacotherapy, your patient experiences troubling motor symptoms, which may include:
Troubling dyskinesia
Motor fluctuations
Refractory tremor
Wearing off –Marked medication intolerance
UTMOVE
Deep Brain Stimulation
Neuromodulation therapy
Reversible
Minimally invasive
Stereotactically implanted electrode delivers high-frequency stimulation
>140,000 patients treated with DBS Therapy worldwide
>2000 scientific articles published on DBS
UTMOVE
Targeting
Imaging
Stereotactic targeting
Physiologic targeting - microelectrode recording & stimulation)
Facilitates programming
of optimal parameters
UTMOVE
DBS in PD
• Best predictor of outcome → RESPONSE to LEVODOPA
• Best candidates:
1. Clear diagnosis of idiopathic PD
2. Good and present response to levodopa: Pre-operative ON/OFF evaluation: at least 30 % improvement in motor UPDRS
3. Disabling symptoms, despite optimized pharmacotherapy
4. Motor fluctuations and/or disabling dyskinesias
5. Normal cognition (absence of dementia)
6. Realistic expectations and good family support
7. Access to programming of stimulators
UTMOVE
Poor Candidates for DBS
• Minimal or absent response to levodopa (except tremor)
• Significant cognitive dysfunction
• Untreated depression or other psychiatric disease
• Uncontrolled hypertension or bleeding diathesis
UTMOVE
Expected Outcomes: DBS for PD
With DBS, OFF-medication motor function becomes more like the best pre-op ON-state
OFF time-reduced by 5.2 hours
Dyskinesia -reduced by >75%
Motor fluctuations-lessened
Cardinal motor signs/symptoms improved
UTMOVE
DBS vs. Best Medical Therapy and Survival
DBS Best Medical Treatment
Mean Gain of “good” ON time in hours per day
4.6 hours “0” hours
Clinically meaningful motor function improvement
71% 32%
Quality of Life PDQ-39 scores
Improved No change
Neurocognitive performance
Mild decrement
Slightly improved
Weaver, et al JAMA, Jan 2009, (1)301:63-73
Ngoga et al ,JNNP; 2013
UTMOVE
UTMOVE
Results of DBS Surgery for PD • GPi DBS
• Reduces contralateral tremor, rigidity, bradykinesia, dyskinesia, & dystonia
• Improves gait & balance
• Medication reduction- minimal
• STN DBS
• Reduces contralateral tremor, rigidity, bradykinesia, & gait/balance dysfunction
• May exacerbate dyskinesia acutely
• Substantial medication reduction common
UTMOVE
Potential Complications and Risks
• Surgery related (UTMOVE team less than 2%)
– Hemorrhage (inherent in any stereotactic procedure)
– Transient confusion
– Infection (typically occurs at neurostimulator site in chest when it does occur)
• Stimulation related
– Usually can be minimized or eliminated by adjusting stimulation settings
– Reversible paresthesia, dysarthria, muscle contraction.
UTMOVE
Components of Successful DBS Therapy
Appropriate patient selection
Accurate surgical DBS lead placement
Optimal DBS programming
Medication management in concert with DBS
Management of side effects
Patient education and support
UTMOVE
DBS : What the Future Holds
• DBS will be increasingly used for movement disorders patients
• Trends toward earlier intervention
4-7 years after diagnosis
**February 2016- FDA approved intervention with DBS in PD at 4 years
EARLY STIM clinical study, NEJM 2013 UTMOVE
Provide comprehensive clinical care for regional, state, national and international communities.
Largest movement disorders program in Texas and Louisiana with the most active DBS program in Texas with an average of 4-8 Stage I cases per month
Deep Brain Stimulation with Microelectrode Recording (MER) facilitates excellent programming outcomes
UTMOVE
Over 5000 patients seen per year
Multiple research projects on Essential tremor, Parkinsonism,
Huntington’s disease and Dystonia.
Partner with HAPS & TIRR - social services, support groups and
physical therapies.
Locations: UT MOVE UTP Clinic, Quentin Mease -Community Hospital ,UT MOVE– The Woodlands
UTMOVE
Our Physicians: • Mya Schiess, M.D. • Erin Furr-Stimming, M.D. • Raja Mehanna, MD • Allison Boyle, MD • Al Fenoy, MD (Neurosurgery) UT MOVE Clinic Direct Tel: 832-325-7080 or 832-325-7081 UT Professional Building Adult Neurology Clinic 6410 Fannin Suite 1014 Houston, Texas 77030
UTMOVE
Navigating the DBS Experience and Procedure
• Key contact person for questions, answers, scheduling post- op programming
• Mike Almaguer, RN at 832 325-7160
UTMOVE